Modern Dental Group Announces 2026 Interim Results 
Merdeka Gold Delivers Strong Q2 Production Ramp-Up as Pani Gold Mine Advances Toward Full-year Growth 
Nissin Foods Announces 2026 Interim Results 
The World’s Leading Minds in Biotechnology Will Meet in Riyadh This September 
Overseas Growth Gathers Momentum as CanSinoBIO’s Global Strategy Unlocks New Opportunities Rockley Photonics, a leading integrated silicon photonic solution provider, closes additional $65 million to accelerate growth
Oxford, UK and Pasadena, California, 29 January 2021 – Rockley Photonics, a leading integrated optics…
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook…
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to…
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021
Press Release Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021…
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in…
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical…
Neuronetics Announces Pricing of $75 Million Public Offering of Common Stock
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a…
10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) — 10x Genomics (Nasdaq: TXG) today announced it…
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; January 28, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that…
Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook…
Neuronetics Announces Proposed Public Offering of Common Stock
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a…
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing…
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong…
GENFIT Announces Two Key Appointments to the Executive Committee
Lille, France; Cambridge, MA; January 28, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage…
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical…
Evelo Biosciences Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical…
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
22nd Century Group to Relocate Headquarters to Buffalo’s Thriving Larkinville District
New space is ideally equipped and located in the heart of Buffalo’s urban renewal WILLIAMSVILLE,…
Invitation to Idorsia’s full year financial results 2020 webcast and conference call
Idorsia will publish its full year financial results 2020 on Thursday February 4, 2021, at…
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE is advancing an “Immunotherapy 2.0” future by leveraging MAbSilico’s artificial intelligence-powered software solutions and…